Overview
MESO market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 12.25
- H
- 12.25
- L
- 11.76
- C
- 11.92
- Vol
- 10,984.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $12.25
- Previous Close
- $12.45
- Day High
- $12.25
- Day Low
- $11.76
- 52 Week High
- $21.48
- 52 Week Low
- $11.76
- 7 Day Return
- -14.83%
- 30 Day Return
- -0.17%
- 90 Day Return
- -30.37%
- 1 Year Return
- -21.06%
- Daily Notional Volume
- $130.9K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.09 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -47.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.74 – $3.31 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- $37.00 Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.5B · P/B 3.00 · P/S 13.74.